Evogene(US:EVGN)2026-03-05 15:00Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024 [16] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [16] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in 2024 [21] - Net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the previous year [30] - Operating loss for Q4 2025 was approximately $5.2 million, an increase from approximately $3.5 million in Q4 2024 [26] Business Line Data and Key Metrics Changes - Lavie Bio Ltd. completed the sale of the majority of its operations, significantly reducing its operational expenses [17] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate [17] - AgPlenus integrated into core operations, focusing on novel ag chemical products [18] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to its seed inventory [18][22] Market Data and Key Metrics Changes - The demand for castor seeds significantly declined, impacting Casterra's operations [18] - The agriculture industry has faced negative performance, affecting collaboration willingness, but there are signs of improvement [40] Company Strategy and Development Direction - The company has focused on two high-impact markets: human health and agriculture, utilizing ChemPass AI for drug development and ag chemicals [8] - A strategic transformation was initiated to streamline operations and enhance long-term value creation [6] - The mission is to become the partner of choice for small molecule discovery and optimization in pharma and agriculture [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of reduced expense levels and the potential for cash inflow from Lavie Bio and Biomica [35] - The company anticipates significant future collaborations with technology and pharmaceutical companies, which could serve as catalysts for growth [36][40] Other Important Information - The company held consolidated cash equivalents of approximately $13 million as of December 31, 2025 [20] - Financing income net for 2025 was approximately $0.6 million, a decrease from approximately $4 million in the previous year [26] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 and revenue sharing from the end product [33] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year [35] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts were identified: technology collaborations, additional pharma collaborations, and ag chemical collaborations [36][40]